Navigating Antitrust Challenges in Life Sciences Private Equity

Calls for removal of allegedly improperly listed patents in the Orange Book continue, with FTC and Congressional pressure leading some pharmaceutical companies to voluntarily delist challenged patents. Teva faces allegations of delaying generic competition for Copaxone and is involved in a legal dispute with Amneal and Cipla. Additionally, a court grants summary judgment in favor of Align Technology in an antitrust suit related to Invisalign, while another court declines to dismiss monopoly claims against HCA Healthcare and Mission Health Systems. The New York Supreme Court dismisses an antitrust complaint filed by the state accusing CVS of illegal tying in the market for 340B drug rebates.